ATEC trades 104.3% below Wall Street's consensus target of $18.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ATEC achieves its forward estimates and maintains a stable P/E multiple of 27.5x. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Alphatec Holdings, Inc. (ATEC) has a Wall Street consensus price target of $18.00, based on estimates from 18 covering analysts. With the stock currently trading at $8.81, this represents a potential upside of +104.3%. The company has a market capitalization of $1.33B.
Analyst price targets range from a low of $14.00 to a high of $24.00, representing a 56% spread in expectations. The median target of $15.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ATEC trades at a trailing P/E of -9.2x and forward P/E of 27.5x. Analysts expect EPS to grow +139.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NUVLNuvalent, Inc. | $9.1B | $123.43 | $132.74 | +7.5% | Hold | — | 18 |
XTNTXtant Medical Holdings, Inc. | $62M | $0.44 | — | — | — | — | — |
GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
NUSNu Skin Enterprises, Inc. | $244M | $5.02 | $11.00 | +119.1% | Hold | 5.0x | 11 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
AHCOAdaptHealth Corp. | $1.3B | $9.65 | $14.40 | +49.2% | Buy | 11.5x | 12 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
Quick answers to the most common questions about buying ATEC stock.
The consensus Wall Street price target for ATEC is $18, representing 104.3% upside from the current price of $8.81. With 18 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ATEC has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $18 implies 104.3% upside from current levels.
ATEC trades at a forward P/E of 27.5313x, representing a moderate valuation. With analysts targeting $18 (104.3% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $24 for ATEC, while the most conservative target is $14. The consensus of $18 represents the median expectation. These targets typically reflect 12-month expectations.
ATEC is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ATEC stock forecast based on 18 Wall Street analysts shows a consensus price target of $18, with estimates ranging from $14 (bear case) to $24 (bull case). The median consensus rating is "Buy".
ATEC trades at a forward P/E ratio of 27.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ATEC, with a "Buy" consensus rating and $18 price target (104.3% upside). 15 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ATEC analyst price targets range from $14 to $24, a 56% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.